Follow-up schedules after treatment for malignant melanoma

British Journal of Surgery

Volumn 95, Issue 11, 2008, Pages 1401-1407

  Francken, A B ^a,b   Accortt, N A ^c   Shaw, H M ^a,d   Colman, M H ^a   Wiener, M ^a   Soong, S J ^c   Hoekstra, H J ^b   Thompson, J F ^a,d  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DATA BASE; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; INFORMATION RETRIEVAL; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RECURRENT CANCER;

EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEW SOUTH WALES; PRACTICE GUIDELINES AS TOPIC; SKIN NEOPLASMS; TIME FACTORS;

EID: 55549145760     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.6347     Document Type: Article

References (26)

1. Francken AB, Bastiaannet E, Hoekstra HJ. Follow-up in patients with localised primary cutaneous melanoma. Lancet Oncol 2005; 6: 608-621.
2. Cascinelli N, Morabito A, Santinami M, MacKie RM, Belli F. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet 1998; 351: 793-796.
3. Balch CM, Soong S, Ross MI, Urist MM, Karakousis CP, Temple WJ et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol 2000; 7: 87-97.
4. Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127: 392-399.
5. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl JMed 2006; 355: 1307-1317.
6. Morton DL. Sentinel node mapping and an International Sentinel Node Society: current issues and future directions. Ann Surg Oncol 2004; 11(Suppl): 137S-143S.
7. Kim CJ, Reintgen DS, Balch CM. AJCC Melanoma Staging Committee. The new melanoma staging system. Cancer Control 2002; 9: 9-15.
8. Francken AB, Shaw HM, Thompson JF, Soong SJ, Accortt NA, Azzola MF et al. The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up. Ann Surg Oncol 2004; 11: 426-433.
9. Azzola MF, Shaw HM, Thompson JF, Soong SJ, Scolyer RA, Watson GF et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer 2003; 97: 1488-1498.
10. McCarthy WH, Shaw HM, Thompson JF, Milton GW. Time and frequency of recurrence of cutaneous stage I malignant melanoma with guidelines for follow-up study. Surg Gynecol Obstet 1988; 166: 497-502.
11. Fusi S, Ariyan S, Sternlicht A. Data on first recurrence after treatment for malignant melanoma in a large patient population. Plast Reconstr Surg 1993; 91: 94-98.
12. Zogakis TG, Essner R, Wang HJ, Foshag LJ, Morton DL. Natural history of melanoma in 773 patients with tumor-negative sentinel lymph nodes. Ann Surg Oncol 2007; 14: 1604-1611.
13. Essner R, Conforti A, Kelley MC, Wanek L, Stern S, Glass E et al. Efficacy of lymphatic mapping, sentinel lymphadenectomy, and selective complete lymph node dissection as a therapeutic procedure for early-stage melanoma. Ann Surg Oncol 1999; 6: 442-449.
14. Clary BM, Mann B, Brady MS, Lewis JJ, Coit DG. Early recurrence after lymphatic mapping and sentinel node biopsy in patients with primary extremity melanoma: a comparison with elective lymph node dissection. Ann Surg Oncol 2001; 8: 328-337.
15. Chao C, Wong SL, Ross MI, Reintgen DS, Noyes RD, Cerrito PB et al. Patterns of early recurrence after sentinel lymph node biopsy for melanoma. Am J Surg 2002; 184: 520-524.
16. Statius Muller MG, van Leeuwen PA, van Diest PJ, Pijpers R, Nijveldt RJ, Vuylsteke RJ et al. Pattern and incidence of first site recurrences following sentinel node procedure in melanoma patients. World J Surg 2002; 26: 1405-1411.
17. Fincher TR, McCarty TM, Fisher TL, Preskitt JT, Lieberman ZH, Stephens JF et al. Patterns of recurrence after sentinel lymph node biopsy for cutaneous melanoma. Am J Surg 2003; 186: 675-681.
18. Wagner JD, Ranieri J, Evdokimow DZ, Logan T, Chuang TY, Johnson CS et al. Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma. Plast Reconstr Surg 2003; 112: 486-497.
19. Gershenwald JE, Colome MI, Lee JE, Mansfield PF, Tseng C, Lee JJ et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 1998; 16: 2253-2260.
20. Borgognoni L, Urso C, Vaggelli L, Brandani P, Gerlini G, Reali UM. Sentinel node biopsy procedures with an analysis of recurrence patterns and prognosis in melanoma patients: technical advantages using computer-assisted gamma probe with adjustable collimation. Melanoma Res 2004; 14: 311-319.
21. Baughan CA, Hall VL, Leppard BJ, Perkins PJ. Follow-up in stage I cutaneous malignant melanoma: an audit. Clin Oncol (R Coll Radiol) 1993; 5: 174-180.
22. Hofmann U, Szedlak M, Rittgen W, Jung EG, Schadendorf D. Primary staging and follow-up in melanoma patients - monocenter evaluation of methods, costs and patient survival. Br J Cancer 2002; 87: 151-157.
23. Fisher SR. Elective, therapeutic, and delayed lymph node dissection for malignant melanoma of the head and neck: analysis of 1444 patients from 1970 to 1998. Laryngoscope 2002; 112: 99-110.
24. de Vries M, Vonkeman WG, van Ginkel RJ, Hoekstra HJ. Morbidity after inguinal sentinel lymph node biopsy and completion lymph node dissection in patients with cutaneous melanoma. Eur J Surg Oncol 2006; 32: 785-789.
25. Richtlijn. Melanoom van de huid. Vereniging van Integrale Kankercentra (VIKC) http://www.oncoline.nl. (accessed 26 August 2008).
26. Francken AB, Shaw HM, Accortt NA, Soong SJ, Hoekstra HJ, Thompson JF. Detection of first relapse in cutaneous melanoma patients: implications for the formulation of evidence-based follow-up guidelines. Ann Surg Oncol 2007; 14: 1924-1933.